[ad_1]
According to the WHO / International Agency for Research on Cancer, 18.1 million cancer cases are diagnosed each year worldwide. Cancer is now the second leading cause of death behind cardiovascular disease. More than ever, it is imperative to continue to look for new ways to treat this devastating disease.
Promising research on multi-agent toxins
Recently, Biotechnologies with accelerated evolution did an interview where they said they believe they "will offer full cancer treatment in one year". Even if it is in the headlines, it is a crucial statement to make. Let's deepen the work they are doing now. The premise behind their treatment involves the use of a multi-agent target toxin treatment treat cancer. In the past, this type of toxin therapy targeting therapy involved the introduction of DNA encoding a protein (possibly an antibody) into a bacteriophage – a virus that infects a bacterium. These proteins can then be displayed on the surface of the virus and interact with its environment.
The treatment of the company involves a similar phenomenon, but with the use of peptides instead of proteins. Peptides consist of two or more amino acids linked together in a chain. They are smaller than proteins, can perform biological functions and, in many ways, are less expensive to replicate.
Most anticancer treatments aim to attack a target in a cell, on the surface of a particular cell or in one of its internal pathways. However, a mutation in one of these targets can render the therapy ineffective. What is done here, with multi-target toxin therapy, is that several peptides of the cancer cell are targeted with a peptide toxin to avoid mutations rendering an therapy ineffective. The higher the number of targets used, the less likely it is that a series of mutations will occur simultaneously, rendering the treatment ineffective. This will help prevent the cancer cell from escaping treatment and continuing to replicate, even with some mutations.
This could also help reduce side effects, since the peptides will aim to attack specific targets of cancer cells that are not usually overexpressed in other healthy cells. In addition, as the peptides are small (they have developed a length of about 12 amino acids) and do not have a rigid structure, this allows them to access the regions of the cell that can be blocked if a larger protein was used.
Overall, they use acombination mode"In a very specific way for an attack of each cancer cell in this therapy. Combinatorial therapy has already been successful, particularly with cancer, HIV and autoimmune diseases. The goal of the company is to personalize each patient in the end by having him send a biopsy and badyzing the receptors on which she overexpresses. The patient would then receive an individualized preparation developed to treat the disease.
It's exciting and potential, but more data needs to be presented. Until now, they have concluded mouse experimentation and found inhibited the growth of human cancer cells which did not affect healthy mouse cells. They are currently working on launching a series of clinical trials, which many people will want to see the findings. Recently, Accelerated Evolution Biotechnologies has written patents on various specific peptides. Although their work has so far been enthusiastic and in the news, their claim to "offer full cancer treatment in one year" is probably premature. Yet I do not know a single person, including myself, who did not expect that.
Joshua Mansour, M.D. is a certified hematologist and oncologist in Stanford, California. It is currently carrying out additional work in the field of Transplantation of Hematopoietic Stem Cells and Cellular Immunotherapy.
CONTACT: Special Guest Jerry McGlothlin, representing Joshua Mansour, M.D.
919-437-0001 [email protected]
Image (s): Shutterstock.com
[ad_2]
Source link
